Exont-based Biopharmaceutical Company Raises $44.9 Million in Initial Public Offering


EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced the full exercise of the underwriters’ option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $5.9 million, in connection with the Company’s previously announced initial public offering of common stock.

After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were sold by Immunome. Immunome’s common stock began trading on the Nasdaq Capital Market on October 2, 2020, under the ticker symbol “IMNM”.

READ:  Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Ladenburg Thalmann & Co. Inc. and Chardan acted as book-running managers for the offering.

A registration statement relating to the offering of these securities has been declared effective by the Securities and Exchange Commission on October 1, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by vising www.sec.gov or from Ladenburg Thalmann & Co. Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, or by calling (212) 409-2000, or by emailing [email protected] or Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004, or by calling (646) 465-9001.

The Company’s announcement does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

READ:  Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Immunome, headquartered in Exton, PA, is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated and an initial focus on oncology and infectious diseases, including COVID-19.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee